| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.RMED.2006.03.031 |
| P8608 | Fatcat ID | release_l4flnerzkvaenjuh2sejfjbh2q |
| P698 | PubMed publication ID | 16713224 |
| P5875 | ResearchGate publication ID | 7068974 |
| P2093 | author name string | Stephen P Peters | |
| Colin Reisner | |||
| Yamo Deniz | |||
| Gary Ferguson | |||
| P433 | issue | 7 | |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 1139-1151 | |
| P577 | publication date | 2006-05-18 | |
| P1433 | published in | Respiratory Medicine | Q2659932 |
| P1476 | title | Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment | |
| P478 | volume | 100 |
| Q92808262 | A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler® to Budesonide/Formoterol Easyhaler® |
| Q92792345 | A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men |
| Q26778799 | A Systematic and Narrative Review of Acupuncture Point Application Therapies in the Treatment of Allergic Rhinitis and Asthma during Dog Days |
| Q58617312 | A humanized mouse model to study asthmatic airway inflammation via the human IL-33/IL-13 axis |
| Q27689386 | A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma |
| Q36579400 | A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma |
| Q37418337 | Activity of the cyclooxygenase 2-prostaglandin-E prostanoid receptor pathway in mice exposed to house dust mite aeroallergens, and impact of exogenous prostaglandin E2. |
| Q35766843 | Adopting Clean Fuels and Technologies on School Buses. Pollution and Health Impacts in Children |
| Q39170238 | Apigenin inhibits TGF-β1 induced fibroblast-to-myofibroblast transition in human lung fibroblast populations |
| Q88656121 | Assessing the Prevalence and Incidence of Asthma and Chronic Obstructive Pulmonary Disease in the Eastern Mediterranean Region |
| Q52579376 | Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma. |
| Q92278023 | Association between body mass index and asthma severity in Arab pediatric population: A retrospective study |
| Q37211041 | Asthma 2008: targeting immunoglobulin E to achieve disease control |
| Q36282175 | Asthma Economic Costs in Adult Asthmatic Patients in Tehran, Iran |
| Q48819326 | Asthma and risk of injury for Australian males aged 6-30 years: a population-based birth cohort study. |
| Q37150901 | Asthma genetics: personalizing medicine |
| Q39192905 | Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy |
| Q41184141 | Asthma referrals: a key component of asthma management that needs to be addressed |
| Q37754970 | Asthma/COPD drugs reflecting disease prevalence, patient adherence and persistence |
| Q92405864 | Azithromycin as an add-on treatment for persistent uncontrolled asthma in adults: protocol of a systematic review and meta-analysis |
| Q39408906 | Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial |
| Q89884029 | Breaking through Restricting Bottleneck for Better Asthma Control |
| Q58781615 | Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort |
| Q64903023 | Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler® for Patients with Poorly Controlled Obstructive Airway Disease: a Real-World Study of Patient-Reported Outcomes. |
| Q89529376 | Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review |
| Q101573965 | Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management |
| Q42360802 | Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate-severe asthma |
| Q44090096 | Control of persistent asthma in Spain: associated factors |
| Q64104682 | Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma |
| Q38680678 | Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting |
| Q44193937 | Development and validation of an asthma knowledge questionnaire for use in Brazil |
| Q42260374 | Development of a mouse model mimicking key aspects of a viral asthma exacerbation |
| Q36870059 | Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. |
| Q40693199 | Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial |
| Q89497781 | Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma |
| Q36733079 | Economic analysis of temperature-controlled laminar airflow (TLA) for the treatment of patients with severe persistent allergic asthma |
| Q38688984 | Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. |
| Q28743191 | Effect of switching to a high-deductible health plan on use of chronic medications |
| Q89566456 | Effectiveness and Patient Satisfaction with Budesonide/Formoterol Easyhaler® Among Patients with Asthma or COPD Switching from Previous Treatment: a Real-World Study of Patient-Reported Outcomes |
| Q46642229 | Effects of inhaled corticosteroids on voice production in healthy adults |
| Q47791323 | Effects of regular exercise on asthma control in young adults. |
| Q92579030 | Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma |
| Q64944782 | Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. |
| Q48506707 | Emodin alleviates alternatively activated macrophage and asthmatic airway inflammation in a murine asthma model. |
| Q88295830 | Evidence for mood-dependent attentional processing in asthma: attentional bias towards health-threat in depressive mood and attentional avoidance in neutral mood |
| Q37908105 | Evidence-based risk assessment and recommendations for physical activity clearance: respiratory disease |
| Q39943337 | Exhaled nitric oxide as a predictor of exacerbation in children with moderate-to-severe asthma: a prospective, 5-month study |
| Q37405580 | Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease. |
| Q40398967 | Exposure Memory and Lung Regeneration |
| Q37231353 | Factors Affecting Recovery Time of Pulmonary Function in Hospitalized Patients With Acute Asthma Exacerbations. |
| Q37621962 | Feasibility of Deploying Inhaler Sensors to Identify the Impacts of Environmental Triggers and Built Environment Factors on Asthma Short-Acting Bronchodilator Use. |
| Q34672401 | Frequent cough in unsatisfactory controlled asthma--results from the population-based West Sweden Asthma study |
| Q34627039 | Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting |
| Q51430338 | IL-13+ Type 2 Innate Lymphoid Cells Correlate with Asthma Control Status and Treatment Response. |
| Q92734808 | Identification of biomarkers in common chronic lung diseases by co-expression networks and drug-target interactions analysis |
| Q37177646 | Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). |
| Q36239388 | Improved asthma control in patients with severe, persistent allergic asthma after 12 months of nightly temperature-controlled laminar airflow: an observational study with retrospective comparisons |
| Q35626866 | In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin |
| Q47737254 | Incentive spirometry combined with expiratory positive airway pressure improves asthma control and quality of life in asthma: a randomised controlled trial. |
| Q39435456 | Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled severe asthma |
| Q44418218 | Is asthma associated with increased risk of injury? |
| Q80625439 | Medication persistence among patients with asthma/COPD drugs |
| Q35130598 | Medication prescribing for asthma and COPD: a register-based cross-sectional study in Swedish primary care |
| Q28080207 | Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential |
| Q61446618 | Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases |
| Q50106766 | Moving toward consensus on diagnosis and management of severe asthma in adults. |
| Q37612221 | MyAirCoach: the use of home-monitoring and mHealth systems to predict deterioration in asthma control and the occurrence of asthma exacerbations; study protocol of an observational study |
| Q36241571 | National asthma observational survey of severe asthmatics in Israel: the no-air study |
| Q40039105 | New perspectives in nanotherapeutics for chronic respiratory diseases. |
| Q35653704 | Non-Anticoagulant Fractions of Enoxaparin Suppress Inflammatory Cytokine Release from Peripheral Blood Mononuclear Cells of Allergic Asthmatic Individuals |
| Q64889098 | Obesity/overweight and asthma control in LEBANESE adults: a cross-sectional study. |
| Q35147247 | Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics |
| Q46104088 | Patient-reported outcomes among omalizumab and salmeterol/fluticasone combination therapy patients |
| Q44811405 | Perception of dietary food items as food allergens in asthmatic individuals in north Indian population |
| Q94456918 | Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects |
| Q38662759 | Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma |
| Q24620510 | Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma |
| Q50053497 | Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. |
| Q45428030 | Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States |
| Q47369399 | Prevalence of asthma and associated factors among male late adolescents in Tabriz, Iran |
| Q35788740 | Prevention of Influenza Virus-Induced Immunopathology by TGF-β Produced during Allergic Asthma |
| Q47598081 | RItA: The Italian severe/uncontrolled asthma registry. |
| Q91953747 | Regulation of IL-17A and implications for TGF-β1 comodulation of airway smooth muscle remodeling in severe asthma |
| Q50889981 | Relating weather types to asthma-related hospital admissions in New York State. |
| Q51602791 | Salmeterol/fluticasone through breath-actuated inhaler versus pMDI: a randomized, double-blind, 12 weeks study. |
| Q41930848 | Severe angina pectoris in asthma attack: a case report. |
| Q55005928 | Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. |
| Q60300301 | Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma |
| Q34070852 | Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children |
| Q37602482 | Subtypes of asthma based on asthma control and severity: a latent class analysis |
| Q89672794 | Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases |
| Q37155167 | The Clinical and Health Economic Value of Clinical Laboratory Diagnostics |
| Q35083012 | The active patient role and asthma outcomes in an underserved rural community |
| Q51345374 | The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. |
| Q33697776 | The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis |
| Q46564503 | The impact of uncontrolled asthma on absenteeism and health-related quality of life |
| Q91132654 | The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress |
| Q38314276 | The relationship between allergen immunotherapy and omalizumab for treating asthma. |
| Q37686313 | The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma. |
| Q37404672 | The validity of induced sputum and bronchoalveolar lavage in childhood asthma |
| Q47970336 | Thoracic CT-MRI coregistration for regional pulmonary structure-function measurements of obstructive lung disease |
| Q59136709 | Tolerability of Omalizumab in Asthma as a Major Compliance Factor: 10-Year Follow Up |
| Q37766243 | Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs. |
| Q24185858 | Yoga for asthma |
| Q24201212 | Yoga for asthma |
Search more.